Scynexis' lead drug scores in vaginal yeast infection trial
Antifungal drug developer Scynexis, which burst into the zeitgeist as one of the sole US-based companies with a Candida auris therapy in human trials …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
